Chemicals · Founded 1989 · www.vinatiorganics.com · BSE 524200 · NSE VINATI ORG. · ISIN INE410B01037
No Notes Added Yet
Business
Vinati Organics Ltd. (VOL) is a leading Indian specialty chemical manufacturer. The company specializes in the production of high-performance specialty chemicals and advanced intermediates, primarily for global markets. Its core business model involves complex multi-step chemical synthesis to produce niche products that cater to various end-user industries such as pharmaceuticals, agrochemicals, dyes & pigments, water treatment, and personal care. The company makes money by selling these value-added chemical products to industrial customers worldwide.
Revenue Mix
Vinati Organics has historically been a dominant player and global leader in two key products: Isobutyl Benzene (IBB), a crucial intermediate for Ibuprofen, and 2-Acrylamido-2-methylpropane sulfonic acid (ATBS), used in water treatment, oil & gas, and personal care. While these two molecules have been significant revenue contributors, the company has been actively diversifying its product portfolio into other high-value specialty chemicals, including butylated phenols (e.g., PTBC, DBPC), A/IBB derivatives, and other performance chemicals, aiming to reduce concentration risk and expand into new application areas. Specific revenue contribution percentages for individual products are not consistently reported but IBB and ATBS remain foundational.
Industry
Vinati Organics operates in the Indian and global specialty chemicals industry, characterized by high technical expertise, significant R&D investment, and stringent quality/regulatory requirements. The industry often has high barriers to entry for specific complex molecules due to process know-how, capital expenditure, and customer qualification periods. VOL is positioned as a niche leader, often being the largest or second-largest producer globally for its flagship products IBB and ATBS. The company's focus on complex chemistry and backward integration provides a competitive edge against general commodity chemical producers.
MOAT
Cost Leadership & Scale: For its core products like IBB and ATBS, Vinati Organics has achieved significant economies of scale, often making it a low-cost producer globally.
Process Expertise: The company possesses deep technical know-how and process efficiencies developed over decades, enabling complex multi-step synthesis and efficient manufacturing.
Customer Stickiness: Specialty chemicals often require lengthy qualification processes by customers, leading to high switching costs once a supplier is approved, fostering long-term relationships.
Backward Integration: Integration into key raw materials for some products helps ensure supply security and cost control.
Entry Barriers: High capital intensity, strict regulatory approvals, and the need for specialized intellectual property create significant barriers for new entrants in its core product lines.
Growth Drivers
Product Diversification: Expansion into new high-value specialty chemicals (e.g., A/IBB derivatives, performance chemicals, custom synthesis projects) reduces product concentration and taps into new market opportunities.
Capacity Expansion: Increasing manufacturing capacities for existing and new products to meet growing global demand.
Global Demand: Growing demand from end-user industries like pharmaceuticals, agrochemicals, and water treatment worldwide.
Import Substitution & "China+1" Strategy: Benefits from the Indian government's push for domestic manufacturing and global customers diversifying supply chains away from China.
R&D Focus: Continuous innovation in developing new molecules and improving processes to enhance product offerings and efficiency.
Risks
Raw Material Price Volatility: Reliance on crude oil derivatives and other specific chemicals means profitability can be impacted by fluctuations in raw material prices.
Product Concentration (historical): While diversifying, historically high reliance on IBB and ATBS meant vulnerability to demand shifts or pricing pressure in these specific markets.
Intense Competition: Facing competition from large global chemical companies and aggressive players, particularly from China.
Regulatory & Environmental Compliance: Operating in the chemicals sector requires strict adherence to environmental, health, and safety regulations, with non-compliance posing operational and financial risks.
Foreign Exchange Fluctuations: Significant export revenues expose the company to currency exchange rate volatility.
Technological Obsolescence: The need for continuous R&D to remain competitive and adapt to evolving customer needs.
Management & Ownership
Vinati Organics is a professionally managed, promoter-driven company. Mr. Vinod Saraf is the Chairman & Managing Director, and his daughter, Ms. Vinati Saraf Mutreja, is the CEO & MD, leading the company's strategic growth initiatives. The promoter family holds a substantial stake in the company, indicating strong commitment and alignment with shareholder interests. The management team is generally perceived to be experienced and has a track record of consistent growth and operational excellence.
Outlook
Vinati Organics is a well-established player in the specialty chemicals sector with a strong competitive position in its core products. The company's strategic focus on diversification into new high-value products, coupled with ongoing capacity expansions and a strong R&D pipeline, positions it for continued growth. The "China+1" strategy and increasing global demand for specialty chemicals offer tailwinds. However, the company faces challenges from raw material price volatility, intense global competition, and the need for successful commercialization of its newer product offerings to sustain its growth trajectory and maintain margins. Its ability to effectively scale new products and navigate dynamic market conditions will be crucial for its future performance.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 448 | 550 | 525 | 553 | 522 | 648 | 542 | 550 | 531 | 604 |
| Other Income | 9 | 10 | 9 | 22 | 7 | 6 | 7 | 16 | 9 | 20 |
| Total Income | 457 | 560 | 534 | 576 | 528 | 655 | 549 | 566 | 540 | 624 |
| Total Expenditure | 333 | 400 | 400 | 420 | 379 | 468 | 382 | 383 | 374 | 434 |
| Operating Profit | 123 | 160 | 134 | 156 | 149 | 187 | 167 | 183 | 165 | 191 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 19 | 20 | 21 | 22 | 22 | 23 | 26 | 26 | 29 | 30 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 103 | 139 | 112 | 134 | 127 | 164 | 141 | 157 | 136 | 160 |
| Provision for Tax | 26 | 35 | 28 | 29 | 33 | 41 | 37 | 42 | 35 | 36 |
| Profit After Tax | 77 | 104 | 84 | 104 | 94 | 123 | 104 | 115 | 101 | 124 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 77 | 104 | 84 | 104 | 94 | 123 | 104 | 115 | 101 | 124 |
| Adjusted Earnings Per Share | 7.4 | 10 | 8.1 | 10.1 | 9 | 11.9 | 10 | 11.1 | 9.7 | 11.9 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 1029 | 954 | 1616 | 2066 | 1900 | 2248 | 2227 |
| Other Income | 45 | 26 | 61 | 52 | 39 | 44 | 52 |
| Total Income | 1074 | 980 | 1676 | 2119 | 1939 | 2292 | 2279 |
| Total Expenditure | 614 | 601 | 1180 | 1493 | 1429 | 1666 | 1573 |
| Operating Profit | 460 | 379 | 496 | 625 | 510 | 627 | 706 |
| Interest | 2 | 1 | 2 | 3 | 5 | 2 | 0 |
| Depreciation | 33 | 43 | 45 | 59 | 73 | 89 | 111 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 425 | 335 | 449 | 563 | 432 | 536 | 594 |
| Provision for Tax | 91 | 66 | 103 | 144 | 109 | 131 | 150 |
| Profit After Tax | 334 | 269 | 347 | 419 | 323 | 405 | 444 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 334 | 269 | 347 | 419 | 323 | 405 | 444 |
| Adjusted Earnings Per Share | 32.5 | 26.2 | 33.7 | 40.8 | 31.1 | 39.1 | 42.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 18% | 12% | 17% | 0% |
| Operating Profit CAGR | 23% | 8% | 6% | 0% |
| PAT CAGR | 25% | 5% | 4% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -30% | -11% | -6% | 18% |
| ROE Average | 15% | 17% | 18% | 20% |
| ROCE Average | 20% | 22% | 23% | 25% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 1279 | 1543 | 1828 | 2213 | 2462 | 2793 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 10 | 0 | 0 |
| Other Non-Current Liabilities | 75 | 83 | 94 | 117 | 160 | 173 |
| Total Current Liabilities | 89 | 108 | 167 | 243 | 218 | 313 |
| Total Liabilities | 1443 | 1734 | 2090 | 2584 | 2840 | 3279 |
| Fixed Assets | 751 | 757 | 873 | 1159 | 1489 | 1724 |
| Other Non-Current Assets | 50 | 322 | 441 | 359 | 361 | 517 |
| Total Current Assets | 643 | 655 | 776 | 1066 | 990 | 1038 |
| Total Assets | 1443 | 1734 | 2090 | 2584 | 2840 | 3279 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 49 | 159 | 176 | 1 | 125 | 0 |
| Cash Flow from Operating Activities | 416 | 219 | 127 | 515 | 332 | 458 |
| Cash Flow from Investing Activities | -197 | -198 | -255 | -329 | -348 | -443 |
| Cash Flow from Financing Activities | -109 | -3 | -47 | -62 | -108 | -16 |
| Net Cash Inflow / Outflow | 109 | 18 | -175 | 124 | -125 | 0 |
| Closing Cash & Cash Equivalent | 159 | 176 | 1 | 125 | 0 | 0 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 32.48 | 26.2 | 33.72 | 40.78 | 31.15 | 39.08 |
| CEPS(Rs) | 35.71 | 30.38 | 38.15 | 46.52 | 38.18 | 47.62 |
| DPS(Rs) | 5.5 | 6 | 6.5 | 7 | 7 | 7.5 |
| Book NAV/Share(Rs) | 124.48 | 150.16 | 177.85 | 199.7 | 237.38 | 269.36 |
| Core EBITDA Margin(%) | 40.32 | 37.02 | 26.96 | 27.65 | 24.79 | 25.9 |
| EBIT Margin(%) | 41.47 | 35.23 | 27.91 | 27.33 | 23 | 23.93 |
| Pre Tax Margin(%) | 41.28 | 35.13 | 27.81 | 27.17 | 22.74 | 23.85 |
| PAT Margin (%) | 32.45 | 28.22 | 21.46 | 20.22 | 17 | 18.03 |
| Cash Profit Margin (%) | 35.67 | 32.72 | 24.27 | 23.07 | 20.84 | 21.96 |
| ROA(%) | 23.13 | 16.96 | 18.13 | 17.94 | 11.91 | 13.25 |
| ROE(%) | 26.09 | 19.08 | 20.56 | 21.6 | 14.31 | 15.42 |
| ROCE(%) | 33.34 | 23.8 | 26.59 | 27.67 | 18.54 | 20.22 |
| Receivable days | 71.58 | 91.6 | 83.09 | 81.2 | 95.43 | 91.07 |
| Inventory Days | 33.05 | 41.14 | 33.68 | 36.03 | 41.45 | 34.07 |
| Payable days | 47.39 | 55.71 | 35.81 | 37.53 | 38.9 | 33.18 |
| PER(x) | 23.69 | 53.43 | 57.89 | 44.34 | 47.23 | 40.43 |
| Price/Book(x) | 6.18 | 9.32 | 10.98 | 9.06 | 6.2 | 5.87 |
| Dividend Yield(%) | 0.71 | 0.43 | 0.33 | 0.39 | 0.48 | 0.47 |
| EV/Net Sales(x) | 7.63 | 15.07 | 12.43 | 9.01 | 8.02 | 7.31 |
| EV/Core EBITDA(x) | 17.08 | 37.94 | 40.45 | 29.75 | 29.9 | 26.24 |
| Net Sales Growth(%) | 0 | -7.25 | 69.3 | 27.9 | -8.05 | 18.33 |
| EBIT Growth(%) | 0 | -21.21 | 34.12 | 25.62 | -22.86 | 23.16 |
| PAT Growth(%) | 0 | -19.32 | 28.7 | 20.93 | -22.95 | 25.47 |
| EPS Growth(%) | 0 | -19.32 | 28.7 | 20.93 | -23.63 | 25.47 |
| Debt/Equity(x) | 0 | 0 | 0.01 | 0.02 | 0 | 0.02 |
| Current Ratio(x) | 7.22 | 6.08 | 4.64 | 4.38 | 4.53 | 3.31 |
| Quick Ratio(x) | 6.17 | 4.95 | 3.59 | 3.42 | 3.62 | 2.61 |
| Interest Cover(x) | 209.58 | 354.55 | 272.91 | 173.95 | 88.27 | 281.72 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.06 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 |
| FII | 4.71 | 4.94 | 5.33 | 5.47 | 5.31 | 3.83 | 3.86 | 3.78 | 3.77 | 3.72 |
| DII | 7.55 | 7.31 | 6.74 | 7.27 | 7.6 | 9.2 | 9.24 | 9.54 | 9.83 | 9.9 |
| Public | 13.68 | 13.47 | 13.65 | 12.98 | 12.81 | 12.68 | 12.62 | 12.4 | 12.12 | 12.1 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.61 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 |
| FII | 0.48 | 0.51 | 0.55 | 0.57 | 0.55 | 0.4 | 0.4 | 0.39 | 0.39 | 0.39 |
| DII | 0.78 | 0.76 | 0.7 | 0.75 | 0.79 | 0.95 | 0.96 | 0.99 | 1.02 | 1.03 |
| Public | 1.41 | 1.4 | 1.42 | 1.35 | 1.33 | 1.31 | 1.31 | 1.29 | 1.26 | 1.25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.28 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +18% | +12% | +17% | — |
| Operating Profit CAGR | +23% | +8% | +6% | — |
| PAT CAGR | +25% | +5% | +4% | — |
| Share Price CAGR | -30% | -11% | -6% | +18% |
| ROE Average | +15% | +17% | +18% | +20% |
| ROCE Average | +20% | +22% | +23% | +25% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.06 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 | 74.28 |
| FII | 4.71 | 4.94 | 5.33 | 5.47 | 5.31 | 3.83 | 3.86 | 3.78 | 3.77 | 3.72 |
| DII | 7.55 | 7.31 | 6.74 | 7.27 | 7.6 | 9.2 | 9.24 | 9.54 | 9.83 | 9.9 |
| Public | 25.94 | 25.72 | 25.72 | 25.72 | 25.72 | 25.72 | 25.72 | 25.72 | 25.72 | 25.72 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 7.61 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 |
| FII | 0.48 | 0.51 | 0.55 | 0.57 | 0.55 | 0.4 | 0.4 | 0.39 | 0.39 | 0.39 |
| DII | 0.78 | 0.76 | 0.7 | 0.75 | 0.79 | 0.95 | 0.96 | 0.99 | 1.02 | 1.03 |
| Public | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.28 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 | 10.37 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.